Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy
8.11.2019 16:00:00 EET | Business Wire | Press release
Gilead Sciences, Inc. (NASDAQ:GILD) today announced data on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV-1 capsid function, that support its further development and potential role as a component in long-acting HIV combination therapy. New data from two Phase 1 studies demonstrate that GS-6207 has potent antiviral activity and a potential dosing interval of up to every six months. In both clinical studies, GS-6207 was generally well tolerated and no serious adverse events were reported. Additional in vitro virology study results suggest GS-6207 can potentially be used in a broad range of people living with HIV regardless of their treatment history. These data were presented at the 17th European AIDS Conference (EACS) in Basel, Switzerland.
“These data reinforce the potential of HIV capsid inhibition as a new long-acting therapeutic pathway to achieving durable viral suppression and support further clinical development of GS-6207,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “Based on these promising results, we look forward to initiating additional studies to evaluate GS-6207 in people living with HIV later this year.”
Gilead will be initiating enrollment of two new clinical trials of GS-6207 in combination with other antiretroviral agents in people living with HIV – a Phase 2/3 study (NCT03739866) in heavily treatment-experienced people living with multidrug resistant HIV-1, as well as a Phase 2 study (NCT04143594) in treatment-naïve people living with HIV. GS-6207 will be administered via a two-week oral lead-in, followed by a subcutaneous injection every six months.
“Long-acting HIV therapy is an exciting approach that could offer more convenience for people living with the disease who prefer not to take a daily pill,” said Eric Daar, MD, Chief of Division of HIV Medicine, Lundquist Institute at Harbor-UCLA Medical Center. “The potency and safety profiles of GS-6207, as demonstrated so far in research and early stage clinical trials, show its potential as a core component of a future long-acting HIV therapy.”
Data on GS-6207 presented at EACS 2019 include:
- Safety and PK of subcutaneous of GS-6207, a novel HIV-1 capsid inhibitor (oral presentation PS13/1)
In this Phase 1 study, 40 healthy participants were randomized to receive either subcutaneous GS‑6207 at doses of 30, 100, 300 or 450 mg (n=8 for each cohort), or placebo (n=8). GS-6207 was generally safe and well tolerated. The most common AEs were injection site erythema (47 percent) and pain (38 percent), all of which were mild and resolved in a few days. The PK profile was characterized by prolonged exposure, with measurable concentrations for at least 32 weeks. These data suggest that GS-6207 may have a potential to be administered up to every six months.
- Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV (poster PE3/17)
This is an ongoing double-blind, placebo-controlled, proof-of-concept Phase 1b study in people living with HIV who are capsid inhibitor-naïve. Participants were randomized to receive either a single dose of GS-6207 (20, 50, 150 or 450 mg) administered subcutaneously (n=6 for each cohort) or placebo (n=2 for each cohort). The primary endpoint was maximum reduction of HIV-1 RNA through 10 days of treatment. Across 20 to 450 mg cohorts, mean maximum reduction in HIV-1 RNA by Day 10 ranged from 1.4 to 2.2 log10copies/mL; these reductions were all significantly greater than those observed in the placebo groups (all p<0.0001). In the blinded review of safety data, GS-6207 was generally safe and well tolerated. The most common AEs were injection site pain (41 percent) and erythema (28 percent), all of which were mild or moderate and resolved in a few days.
- HIV-1 from antiretroviral-naïve and experienced patients lack capsid substitutions associated with GS-6207 in vitro resistance (poster PE13/15)
In this analysis, a database of samples from 1,500 people living with HIV, including treatment-naïve (n=500), treatment-experienced but protease inhibitor (PI)-naïve (n=500) and treatment-experienced with PI failure with or without major PI resistance mutations (n=500), was screened for the presence of capsid mutations associated with in vitro resistance to GS-6207 (L56I, M66I, Q67H, K70N, N74D, N74S and T107N). None of the seven GS-6207 resistance mutations was detected among the patients studied. These results suggest a very low likelihood (<1 in 1500) of pre-existing resistance mutations against GS‑6207 among people living with HIV.
- Absence of naturally existing resistance against the HIV-1 capsid inhibitor GS-6207 in HIV-1 primary isolates (poster PE13/22)
This study assessed the potency of GS-6207 in HIV-1 primary isolates with naturally occurring gag polymorphisms, which could be associated with loss of potency. The HIV-1 isolates were sourced from 51 people living with HIV, including treatment-naïve (n=15) and treatment-experienced (n=36) people. GS-6207 displayed high potency, with an EC50 of 95 pM, that was not affected by the presence of gag polymorphisms and/or PI resistance mutations. This result demonstrates the absence of naturally occurring resistance against GS-6207 in this sample of both treatment-naïve and treatment-experienced people living with HIV.
GS-6207 is an investigational therapy and not approved by any regulatory body globally; its safety and efficacy have not been established. There is no cure for HIV or AIDS.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it’s estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that we may not be able to complete the additional clinical studies of GS-6207 in the currently anticipated timelines or at all. There is also the possibility of unfavorable results from additional studies of GS-6207, and Gilead may make a strategic decision to discontinue development of GS-6207 if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, GS-6207 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574- 3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005193/en/
Contact information
Greg Mann, Investors
(424) 322-1795
Ryan McKeel, Media
(650) 377-3548
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 03:30:00 EET | Press release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for the first time reflects both the strength of India's technology ecosystem and the growing role its enterprises play in shaping global supply chai
Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 23:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 23:00:00 EET | Press release
Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 23:00:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 19:00:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an audience of over 300 million players, the survey shows an engaged audience with established spending habits: 84% of respondents call themselves gam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
